Career Recruitment Site

About Astellas VISION

On the forefront
of healthcare change
to turn innovative
science into
VALUE for patients

The environment around Astellas

There are still many diseases for which treatment satisfaction is low in the world, and new drugs that bring VALUE to patients are eagerly awaited. In addition, there are many new opportunities to pursue in the business environment surrounding Astellas, including the realization of therapeutic methods such as cell therapy and gene therapy, as well as new technologies in various fields that can be applied to medicine. On the other hand, how and by whom healthcare costs should be borne is a major issue in each country. Thus, it is important not only to think about creating a good product, but to work together with a broad range of stakeholders to deliver new VALUE to patients.


Astellas is committed to creating VALUE through innovation in the business of developing new pharmaceutical products. We will continuously identify business opportunities by taking a multifaceted approach towards environmental changes in healthcare. By looking at the entire healthcare system, we will make sure to deliver this new VALUE to patients, and ensure our own growth. With this in mind, the concept of our VISION is: “On the forefront of healthcare change to turn innovative science into VALUE for patients.”

Corporate Strategic Plan 2021

We are working on a Corporate Strategic Plan 2021 with a steadfast commitment to making this VISION a reality.

Evolved strategy. Ambitious goals.
Transformative execution.
Same deep commitment to our VISION.

Strategic Goals

1.Enable patients to achieve better outcomes
2.Translate innovative science into proven VALUE
3.Advance the Rx+ business
4.Deepen our engagement in sustainability

Organizational Health Goals

Transforming Astellas’ ability to execute by fostering a culture where innovation, talent and collaboration come together to reach ambitious goals

Performance Goals

  • 01 Revenue

    XTANDI and Strategic products*sales≥ ¥1.2T in FY2025

  • 02 Pipeline

    Focus Area projects expected sales≥ ¥0.5T in FY2030

  • 03 Core Operating
    Profit Margin

    ≥ 30% in FY2025

Market Cap ¥7T

* XOSPATA, PADCEV, zolbetuximab, Evrenzo, fezolinetant, AT132